My key research interest within the Bahn lab is to develop functional cytomic models for biomarker elucidation and drug discovery in psychiatric disorders using primary patient samples exvivo and induced pluripotent stem (iPS) cells. For my undergraduate degree I studied Biological Sciences with specialization in Neurosciences at the University of Edinburgh (UK). I have over five years of experience in the biotech industry working on personalized medicine and drug discovery at Vivia Biotech (Spain) and Novasite Pharmaceuticals (San Diego, USA).
Sureyya Ozcan PhD
I am a bioanalytical chemist specialising in mass spectrometry with clinical, biological, nutritional and pharmacological applications. I hold a BSc degree (Gazi University, Turkey) and PhD degree in Chemistry (University of California, Davis, USA). My research interest is developing Mass Spectrometry based tools for the discovery of diagnostic and prognostic disease markers. I primarily use an `OMICS` approach; Glycomics, Glycoproteomics and Proteomics to unravel the complexity of biological systems. I am also interested in developing protocols for the characterization of glycans. glycoproteins and therapeutics.
I graduated as a chemical engineer (biomedical option) from the University of Alberta in Edmonton, Canada in 2011. During my studies, I conducted undergraduate research into protein adsorption on nanofibre surfaces at the National Institute for Nanotechnology. I also completed an internship at the Ecole des Mines de Nancy in France, where I investigated the dissolution kinetics of refractory metals in molten titanium alloy baths. I devoted time in my last semester to developing a dynamic model of autonomic nervous system response in chronically stressed individuals, during which I developed a strong interest in data analysis. After joining the Bahn laboratory as a PhD student in October 2011, I have started an analysis of molecular gender differences in schizophrenia and major depressive disorder patients. This is based on the observation that there is a gender difference in the risk, age of onset and disease progression for various neuropsychiatric disorders.
Jakub Tomasik PhD
My project is focused on novel treatment approaches for schizophrenia. I am particularly interested in improving response rates to current antipsychotic medications by applying biomarker strategies in the clinical decision making process as well as in the discovery of novel neuroleptic drugs in pre-clinical models and clinical trials. I have a strong background in biomarker discovery and statistical modelling from my PhD studies in Neuroscience under the supervision of Prof. Bahn at Cambridge University and the Erasmus Medical Centre in Rotterdam, my MSc studies in Biotechnology at Jagiellonian University in Krakow and my internship at the Max Planck Institute of Psychiatry in Munich.